search this site
- home
- highlights
- sinclair at a glance
- growing our operations worldwide
- products:oral health
- products:dermatology
- chairman´s statement
- business review:operational
- business review:financial
- board of directors
- senior management
- directors´ report
- corporate governance report
- directors´ remuneration report
- independent auditors´ report
- consolidated income statement
- balance sheets
- statements of changes in shareholders´ equity
- cash flow statements
- notes to the financial statements
- 1. Accounting Policies
- 2. Financial risk management
- 3. Segmental information
- 4. Exceptional operating items
- 5. Operating profit/(loss)
- 6. Employees and Directors
- 7. Finance Income and costs
- 8. Taxation on Loss on ordinary activites
- 9. Loss for the financial year
- 10. Earnings/(Loss) per Share
- 11. Goodwill
- 12. Intangible assets
- 13. Property, plant and equipment
- 14. Investments
- 15. Inventories
- 16. Trade and other receivables
- 17. Trade and other payables
- 18. Borrowings
- 19. Non-current tax
- 20. Financial Instruments
- 21. Called-up share capital
- 22. Options and Warrants over Shares of Sinclair Pharma plc
- 23. Share-based payments
- 24. Other Reserves
- 25. Cash Flows from Operating Activities
- 26. Operating lease commitments
- 27. Capital Commitments
- 28. Related Party Transactions
- corporate advisors
10. EARNINGS/(LOSS) PER SHARE
The basic earnings/(loss) per share has been calculated by dividing the profit/(loss) for the year, by the weighted average number of shares in existence for the year. Shares held by the Employee’s Share Trust, including shares over which options have been granted to Directors and staff, have been excluded from the weighted average number of shares for the purposes of calculation of the basic loss per share.
Diluted earnings per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. Potential ordinary shares of the Company are share options, warrants and awards. A calculation has been undertaken to determine the number of shares that could have been acquired at fair value (determined as the average annual market price of the Company’s shares) based on the monetary value of the subscription rights attached to outstanding options, warrants and awards.
2008 |
2007 |
|
| Profit/(loss) attributable to equity shareholders (£’000) | 3,337 |
(4,208) |
| Weighted average number of shares | 87,241,256 |
86,915,094 |
| Adjustment for share options, warrants and awards | 4,523,701 |
n/a |
| Diluted weighted average number of shares | 91,764,957 |
86,915,094 |
| Basic profit/(loss) per share | 3.8p |
(4.8)p |
| Diluted profit/(loss) per share | 3.6p |
(4.8)p |